Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anja Sandström manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to SAEED, KAMAL A, who is also the busiest examiner for the portfolio with 1 pending action. The concentration of work is high, as the portfolio involves only 1 distinct examiner and 1 distinct art unit.
This narrow distribution suggests a highly focused prosecution strategy or a very early-stage portfolio. Because all activity is limited to 1 distinct art unit, the applicant faces a singular set of examination standards and procedural norms. Practitioners should note that the entire pending workload rests with SAEED, KAMAL A, making this individual the primary point of contact for the current patent efforts.
The lack of diversity in examiners means the portfolio's progress is entirely dependent on the specific throughput and tendencies of a single office official. For an applicant in Biotechnology & Pharmaceuticals, this centralization can simplify communication but increases the impact of a single examiner's perspective. This structure requires precise alignment with the examiner's technical interpretations to ensure successful outcomes across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556116 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | SAEED, KAMAL A | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556116 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | SAEED, KAMAL A | 1626 | §112 | Non-Final OA | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnja Sandström has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kamal A Saeed has the most, with 1 of Anja Sandström's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
